Cargando…
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies
Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells. In mammals, at least three proteins (α, β1, and β2), generated from two different genes, gsk-3α and gsk-3β, are widely expressed at both the RNA and protein levels although some tissue...
Autores principales: | Medina, Miguel, Garrido, Juan Jose, Wandosell, Francisco G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186940/ https://www.ncbi.nlm.nih.gov/pubmed/22007157 http://dx.doi.org/10.3389/fnmol.2011.00024 |
Ejemplares similares
-
Deconstructing GSK-3: The Fine Regulation of Its Activity
por: Medina, Miguel, et al.
Publicado: (2011) -
Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?
por: Flynn, Cassandra M., et al.
Publicado: (2023) -
The role of extracellular Tau in the spreading of neurofibrillary pathology
por: Medina, Miguel, et al.
Publicado: (2014) -
Editorial: Untangling the Role of Tau in Physiology and Pathology
por: Medina, Miguel, et al.
Publicado: (2020) -
Neuronal and glial purinergic receptors functions in neuron development and brain disease
por: del Puerto, Ana, et al.
Publicado: (2013)